Dosimetric Coverage of the Prostate, Normal Tissue Sparing, and Acute Toxicity with High-Dose-Rate Brachytherapy for Large Prostate Volumes

Yang, George; Strom, Tobin J.; Wilder, Richard B.; Shrinath, Kushagra; Mellon, Eric A.; Fernandez, Daniel C.; Biagioli, Matthew C..
Int. braz. j. urol ; 41(3): 435-441, May-June 2015. tab
Artículo en Inglés | LILACS | ID: lil-755887

Documentos relacionados

  1. LDR brachytherapy offers superior tumor control to single-fraction HDR prostate brachytherapy: A prospective study.
  2. Local salvage of radiorecurrent prostate cancer.
  3. The use of Lutetium-177 PSMA radioligand therapy with high dose rate brachytherapy for locally recurrent prostate cancer after previous definitive radiation therapy: a randomized, single-institution, phase I/II study (ROADSTER).
  4. Metastasis and Mortality in Men With Low- and Intermediate-Risk Prostate Cancer on Active Surveillance.
  5. Fewer systematic prostate core biopsies in clinical stage T1c prostate cancer leads to biochemical recurrence after brachytherapy as monotherapy.
  6. Focal high-dose-rate brachytherapy for localized prostate cancer: toxicity and preliminary biochemical results.
  7. Biochemical failure-rate and preservation of erectile function after prostate seed brachytherapy in early-onset prostate cancer.
  8. Safety and efficacy associated with single-fraction high-dose-rate brachytherapy in localized prostate cancer: a systematic review and meta-analysis.
  9. Dosimetric coverage of the prostate, normal tissue sparing, and acute toxicity with high-dose-rate brachytherapy for large prostate volumes.
  10. Patient-reported Outcomes After External Beam Radiotherapy With Low Dose Rate Brachytherapy Boost vs Radical Prostatectomy for Localized Prostate Cancer: Five-year Results From a Prospective Comparative Effectiveness Study.